

# The On-Demand Era of Human Tissue Research : Bioprinted Skin Equivalents



The webinar discusses the promise of bioprinted skin equivalents in improving the accuracy of skin research with applications in toxicology, basic physiology and disease modeling. With the promise of customized selections of cells and on-demand printing of tissues, bioprinted skin equivalents offer values of reducing time and boosting the quality of research.

## ABOUT PRESENTER





## Ms. Da-Yae Lee


Senior Bio-Consultant  
Project Leader, Global Business Development  
ROKIT Healthcare

Lee is a part of the “Bioprinting Applications” team commercializing three-dimensional human skin equivalent models, aimed at supporting the animal 3Rs (Reduction, Replacement, Refinement) and improving the accuracy of human skin research.

Before joining ROKIT Healthcare, Da-Yae was a research assistant at the MIT Koch Institute for Integrative Cancer Research and Brigham and Women’s Hospital Crohn’s and Colitis Center in Boston, USA, with experiences both at the bench and in clinical trial coordination. She has a B.A. in Biochemistry from Smith College in Massachusetts, USA.




## ON-DEMAND HUMAN TISSUE RESEARCH: APPLICATIONS OF BIOPRINTING IN SKIN



2020. 06. 11

Da-Yae Lee

Senior Bio-Consultant





**Control  
of the Time**



**Desired  
Design**



**High  
Quality**



A laboratory scene with a white rabbit, a gloved hand holding a syringe, a microscope, and a flask with colorful liquids.

# PROBLEM

# END OF DEPENDENCE OF ANIMAL TESTINGS

NEWS

## Cosmetic animal testing bill tabled in House of Commons

By Holly Lake. Published on Apr 12, 2019 9:59am

## US states join global push to ban animal-tested cosmetics

By Associated Press

February 3, 2020 | 11:32am



- BAN ON ANIMAL TESTING FOR COSMETICS +/- OR BAN ON SELLING NEWLY ANIMAL-TESTED COSMETICS
- COUNTRIES WHERE BCF IS ACTIVE
- POLL DATA: PUBLIC SUPPORT FOR A NATIONAL COSMETICS TESTING BAN



### United States

Leading efforts to support federal legislation that will phase-out animal testing and prohibit the import of animal tested cosmetics.

---



### Canada

Working with politicians to amend Canada's Food and Drugs Act to ban animal testing for cosmetics.

# LIMITATIONS OF ANIMAL & 2D MODELS

## Vs. RABBIT TEST

### Comparison of human skin irritation patch test data with *in vitro* skin irritation assays and animal data


DAGMAR JÍROVÁ<sup>1</sup>, DAVID BASKETTER<sup>2</sup>, MANFRED LIEBSCH<sup>3</sup>, HANA BENDOVIÁ<sup>1</sup>, KRISTINA KEJLOVÁ<sup>1</sup>, MARIE MARRIOTT<sup>4</sup> AND HELENA KANDÁROVÁ<sup>5</sup>

<sup>1</sup>National Institute of Public Health, Prague, Czech Republic, <sup>2</sup>DABMEB Consultancy Ltd., Sharnbrook, UK, <sup>3</sup>ZEBET, Federal Institute for Risk Assessment, Berlin, Germany, <sup>4</sup>Safety and Environmental Assurance Center, Unilever Colworth Laboratory, Bedford, UK, <sup>5</sup>MatTek Corporation, MA, Ashland, USA

Table 4. Concordance of classifications

#### Classification methods

- Rabbit test ▶ 4-hr HPT
- 4-hr HPT PT ▶ Rabbit test
- 15 min/42 hr EPISKIN assay ▶ Rabbit test
- 15 min/42 hr EpiDerm assay ▶ Rabbit test
- 15 min/42 hr EPISKIN assay ▶ 4-hr HPT
- 15 min/42 hr EpiDerm assay ▶ 4-hr HPT



Concordance of classifications is calculated on the basis

Sensitivity	Specificity	Accuracy (%)
100.0% (5/5)	45.0% (9/20)	56.0
31.3% (5/16)	100% (9/9)	56.0
50.0% (7/14)	66.7% (6/9)	56.5
43.8% (7/16)	77.8% (7/9)	56.0
100.0% (3/3)	65.0% (13/20)	69.6
80.0% (4/5)	75.0% (15/20)	76.0

f results from ECVAM SIVS study (16).

## Vs. 2D HUMAN MODEL







### Culture of skin cells in 3D rather than 2D improves their ability to survive exposure to cytotoxic agents

Tao Sun<sup>a</sup>, Simon Jackson<sup>a</sup>, John W. Haycock<sup>a</sup>, Sheila MacNeil<sup>a,b,\*</sup>

<sup>a</sup> Department of Engineering Materials, Sheffield University, Kroto Research Institute, Broad Lane, Sheffield S3 7HQ, UK

<sup>b</sup> Division of Clinical Sciences, Sheffield University, Northern General Hospital, Sheffield S5 7AU, UK


Received 6 October 2005; received in revised form 6 December 2005; accepted 12 December 2005





# LIMITATIONS OF EXISTING 3D MODELS


Traditional 3D fabrication methods for human tissue include:




## LIMITATIONS

- **Difficult control** over cell, material composition and pore sizes
- Adverse effects of **long pre-processing**
- **Data inconsistency** due to human error
- **Reliance on animal-derived components**
- **Necrotic cores**

3D Bioprinting Approach



Manual Casting Approach








SOLUTION

# DO BETTER RESEARCH WITH ROBOTIC SOLUTION

**COMPLEX  
ARCHITECTURE**


**6-PRINTHEADS**



## RETINA




## BONE



Photomicrograph: Areolar connective tissue, a soft packaging tissue of the body (330x).



## MUSCLE & HEART




# DO BETTER RESEARCH WITH ROBOTIC SOLUTION

**HUMAN CELLS & TISSUE**

**INCUBATOR & STERILIZER**



**PLASMA STERILIZER**



**HEPA H14 FILTER**







# DO BETTER RESEARCH WITH ROBOTIC SOLUTION

**HIGH-THROUGHPUT**

**UP TO 384-WELL**




## Mini-Liver Drug Development



## Safer, Contained Vaccine Research



## PCR Genotyping








# DO BETTER RESEARCH WITH ROBOTIC SOLUTION

**DIVERSE MATERIALS**

**HYBRID TECHNOLOGIES**



SOFT	HARD
Alginate	PLA
Agarose	PCL
Chitosan	PLGA
Collagen/ColMA	PLLA
Fibrin	Nano-ceramics
Gelatin/GelMA	Polyurethane
Pluronic F-127	Tri-calcium Phosphate
Hyaluronic acid	Hydroxyapatite (HAp)
Cellulose	Bioactive glass

# FAST TRACK TO MEDICAL COMMERCIALIZATION

Dr. INVIVO has already been used to treat patients in the operating room!


cGMP-READY

HOSPITAL-USE  
CASES

(2019) SOFT TISSUE: DIABETIC FOOT ULCER SKIN



(2020) HARD TISSUE: CUSTOMIZED BONE IMPLANTS



# TODAY'S FOCUS: BIOPRINTING HUMAN SKIN

## IN VIVO (IN SITU)





Figure 8. Wound Closure (Healing Rate) Evaluation: compared to control (showing more depth due to slow regeneration, HumaTein treated wound filled with neo-tissue and the tissue contraction is less noticeable)



Wound Healing  
In-Hospital Solution

## IN VITRO



Toxicology  
Basic Skin Research (Physiology)  
Disease Modeling



# WORLD'S FIRST DFU SKIN REGENERATION WITH INVIVO®

⑤ Remove the scaffold & apply only MA-ECM, a shape of dermal patch to the patient's wound



⑥ Follow up the wound size and skin regeneration



4weeks



5weeks



10weeks

④ Printing scaffold & MA-ECM

Dr.INVIVO  
(3DBioprinter)

① Harvesting adipose-tissue by liposuction


② Nano-fat processing with filters

③ Preparing bio-inks






# 20 PATIENTS: 100% EPITHELIALIZATION




➔ **100% Epithelialization**



**(Wound Healing Rate: Ave. 4week )**




# INTEGRATED 3D SCAN-PRINT SYSTEM




## Scanning Program




**Pointing affected area by One-click**  
- Measuring printing time based on size, volume of affected area



① Curve Type



② Planar Type



③ Flat Type

**Automatic simulation of affected area and recovered simulation**


## Wound Recovery Program



## Application



Scaffold Printing




Bioink1 Printing





Bioink2 Printing

## Printing



DFU INVIVO


# IN SITU – CURVE PRINT SYSTEM



**Dr. INVIVO 4D6**  
**One-Touch**  
**Horizontal -> Vertical Slicing**


# HUMAN SKIN EQUIVALENT (HSE): COMPOSITION

## EPIDERMIS




- Keratinocytes (90-95% of the components)
  - Corneocytes (terminally differentiated)
- Langerhans cells (immunological response)
- Merkel-Ranvier cells (sensory reception)
- Melanocytes (skin pigmentation, UV protection)

## DERMIS



- Fibroblasts: majority, with dense fibers
- Collagen and elastin fibers: structure, tensile strength, and elasticity

## HYPODERMIS




- Adipose cells: fat storage and provides insulation and cushioning




# CRITERIA FOR SUCCESSFUL HSE




Considerations of stratified cell crosstalk and signaling



Considerations of diverse cell types (i.e. keratinocytes, fibroblasts, immune cells and bacteria)



Considerations of human-to-human variations (age, race, hair, etc.)





Adherence to regulatory guidelines for *in vitro* skin tests

# APPLICATIONS OF THE HSE


## Corrosion / Irritation



## Absorption / Penetration




## Sensitization




C. Rodrigues Neves and S. Gibbs, Curr Top Microbiol Immunol 2018

## Lightening/Melanogenesis




# APPLICATIONS OF THE HSE


## Drug Screening / Delivery




## Phototoxicity / UV



## Anti-aging



## Genotoxicity






# PUBLICATIONS USING HSE


## RECONSTRUCTED SKIN-DISEASE MODELS

### CANCER



**Skin reconstructions of different stages of melanomas.**  
Metastatic melanoma cells grow in all directions and invade deep into the dermis as single cells or clusters.

### WOUND HEALING



Control      3h after injury      24h after injury      72h after injury

Figure 5: Wound healing process after injury with a laser

**Wound healing process after injury with a laser.**

### FUTURE DIRECTION


**Skin reconstruct models bridge the gap between in vitro and in vivo studies. They will lead to a better understanding of which genes are involved in transformation and how stem cells contribute to that transformation.**

J. Vis. Exp. (54), e2937, doi:10.3791/2937 (2011).

# PUBLICATIONS USING HSE

## RECONSTRUCTED SKIN-DISEASE MODELS


### PSORIASIS



**Macroscopic and histological analyses of the tissue-engineered psoriatic substitutes.** The tissue-engineered psoriatic substitutes treated with cytokines display further irregular epidermis with protuberances and thinner regions, which is typical of psoriatic tissues.

Regen Med, 11 (6), 545-57 (2016)

### ATOPIC DERMATITIS



**Difference between normal RE and CRE model.** The inflammatory cocktail alters the morphology and epidermal protein expression in reconstructed epidermis.

### FUTURE DIRECTION

Skin reconstruct models bridge the gap between in vitro and in vivo studies. They will lead to a better understanding of which genes are involved in transformation and how stem cells contribute to that transformation.

J. Vis. Exp. (54), e2937, doi:10.3791/2937 (2011).

# PUBLICATIONS USING HSE

## RECONSTRUCTED HUMAN SKIN VARIATION MODELS

### AGING

Property characterization of reconstructed human epidermis equivalents, and performance as a skin irritation model




Fig1. Morphological study of human epidermis equivalent.




Fig2. Comparison of reconstructed human epidermises with keratinocytes isolated from donors of different ages (3, 15, 24, 39, 45 or 62 years old).

Fig3. Immunodetection of various markers in the model of epidermal equivalent (a) and in native skin (b).

### CONCLUSION

- ✓ The model presented in this study is a 3D reconstructed human epidermis model developed from keratinocytes that were isolated from human skin.
- ✓ It is alternatively possible to select the age, the gender, or the ethnicity of the donors, and the differentiation stage of the tissue in order to develop specific models.

### HAIR

Engineered building blocks to print endogenous tissues and complex organs in vitro




Fig1. Schematic procedure for human skin equivalent




Fig2. hair implantation inside the maturation chamber (b) and 3D dermis equivalent with hair after 2 weeks of maturation time (c)




Fig3. biohybrid with exogenous hair (a); H&E staining of HSE with hair implantation (b-c); immunofluorescence analysis of hair follicle (Versican, CD133) (d); H&E staining of exogenous hair bulb (e-f).

Alessandro Garziano on 01 June 2016.  
SCIENTIFIC REPORTS | (2018) 8:13434  
Toxicology in Vitro(2018), S0887-2333(18)30355-2

### CONCLUSION

- ✓ The goal of this study is to develop skin substitutes with greater homology to native skin, in terms of dermis layer, extra cellular matrix, epidermal differentiated layer, and hair follicles.
- ✓ The introduction of anagen hairs in our 3D human skin equivalent, demonstrates the relevance of the endogenous ECM. The mature hair follicles are able to growth in several kind of conditions, fresh medium, conditioned medium, in exogenous ECM and fibroblasts



# AGE OF ON-DEMAND RESEARCH SOLUTIONS



# EPI<sub>TEM</sub>, THE HUMAN SKIN ON-DEMAND

## *Epi<sub>Tem</sub>: 3D Bioprinted HSE*

*"I'D LIKE TO USE READY-TO-USE 3D BIOPRINTED HUMAN EPIDERMIS"*



- *EPI<sub>TEM</sub>: EPIDERMIS*
- *EPI<sub>TEM</sub> FT:  
EPIDERMIS +  
DERMIS*

## *Epi<sub>Tem</sub> Creator Kit*

*"I'D LIKE TO EXPLORE DIVERSE HUMAN SKIN STUDY DESIGNS ON MY OWN"*



Bioprinter, Dr. INVIVO

+




Bioink KIT

+



Media KIT

+



Cell KIT


+



Protocol


# EPI-TEM VALIDATION: STRUCTURAL & FUNCTIONAL

## Feature



**Fig 1.** Epi-tem had the multi-layered and highly differentiated epidermis.


Histological morphology is observed following H&E staining after 18 days of reconstruction and characterization of the localization proteins expression.



**Fig 2.** Immunohistochemistry results of (A) Cytokeratin10 and (B) p63.

IHC was performed by histological cross-sections of the Epi-tem to characterize the expression localization of these proteins.


## Barrier Function Test



**Fig 3.** Barrier function result depends on time exposure.

Exposure Time 50 (ET50) corresponds to the time to observe 50% cell mortality after treatment of 1% Triton X-100 on Epi-tem.

## Irritation Test



**Fig 4.** Irritation test results of 20 chemicals according to TG439 guidelines.

Non-irritation chemicals show over than 50% cell viability, but classified chemicals represent less than 50% viability.





# Discover EpiTem

**Advanced, Customized  
Human Skin Equivalent**

*To be used  
in Cosmetic, Chemical &  
Pharmaceutical industry*



*Whitening/Aging model Test*



*Drug Screening/Delivery Test*



*Absorption/Penetration Test*



*OECD TG431/439*

# BIOPRINTING: AUTOMATED, HUMAN, SMART SOLUTION

BIOPRINTING IS A PLATFORM BIO-MANUFACTURING TECHNOLOGY WITH APPLICATIONS FOR ALL MAJOR-FUNDED RESEARCH FIELDS

Organ systems	Cell Types used in 3D Bioprinting
Cardiovascular tissue	ESCs (8) MSCs(10, 18, 19) Cardiac progenitor cells (11, 12, 14) iPSC-derived cardiomyocytes (13, 20) Adipose-derived stromal vascular fraction cells (21) Myoblasts (15, 19) <sup>a</sup>
Musculoskeletal tissue	MSCs (36) MDSCs (35) Myoblasts (31, 32) <sup>a</sup>
Neural tissue	ESCs(41, 42) MSCs (7, 43) Glioma stem cells (40) NSCs(39, 46, 47)
Hepatic tissue	iPSC-derived (51, 54) or ESC-derived(54) hepatocyte-like cells iPSC-derived hepatic progenitor cells (57) ADSCs (57, 59) Hepatocellular carcinoma cells (52) <sup>a</sup>
Adipose tissue	ADSCs(61)
Skin tissue	AFSCs (65) MSCs (65, 66, 67, 70) ADSCs (70) Epithelial progenitor cells (69)


**CELLS**



**PLATFORM**



**MANUFACTURED HUMAN TISSUES**



Bioink polymers	Bioink concentration	Applications
Collagen	0.223%	Perfusable artificial tissue
Collagen/alginate	15 mg/mL collagen 0.1 g/mL alginate	Cartilage TE
Gelatin	10–20%	TE, stem cell, & cancer
Gelatin/ Agarose	0.06%	Heart valve regenera
Gelatin with transglutaminase (TG)	5% (w/v) with 2.5–20 un TG/g of gelatin	Tumor modeling & regenera medicine.
Hyaluronic acid (HA) with gelatin	0.5% (w/v) HA-Ph, 3.0% (w ) Gelatin-Ph, Ru(II) & SPS	TE & regenerative medicine
HA with methylcellulose (MC)	2.0 wt% HA, 5–9 wt% of MC	TE
Fibrin	10 mg/ml, 20 U/ml	Nerve TE
Silk/PEG	5–10% w/v	TE
Decellularized the adipose (adECM), cartilage (cdECM) & heart (hdECM)	3%	TE, in vitro drug screening & tiss ue/cancer model.
HdECM with vitamin B2 & VEGF	20 mg/MI	Cardiac TE

**BIOINKS**

• Source: Ong, C. S. (2017). 3D bioprinting using stem cells. *Nature*. & Gopinathan, J. (2018). Recent trends in bioinks for 3D printing. *Biomaterials*.



# Thank You for Pioneering with Us

*Contact Us At:*



*Authorized Distributor of  
Rokit Healthcare  
INVIVO 4D/4D6 bioprinters  
& Bioinks in US*

**Senthil S PhD**  
General Manager  
Senthil.s@onsbio.com  
www.onsbio.com



*Organ Regeneration  
Platform Company*

*4D "Regenerator"  
Human Cell-Based BioInks  
Clinical Product Development*

**Da-Yae Lee**  
Senior Bio-Consultant  
invivo@rokit.co.kr  
www.rokithealthcare.com

